Compare Stocks: SRZN, NBTX, VOR, and CVAC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
NBTX Nanobiotix	$25.83 +7.0%	$33.80	$14.78 ▼ $57.14	$1.23B	0.79	149,622 shs	165,343 shs
SRZN Surrozen	$25.32 +0.7%	$23.69	$11.39 ▼ $37.83	$291.88M	0.47	1.22 million shs	118,837 shs
VOR Vor Biopharma	$18.94 -0.5%	$21.31	$6.50 ▼ $28.66	$1.13B	1.78	1.02 million shs	817,350 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.22%
NBTX Nanobiotix	+7.00%	+21.38%	-25.13%	-34.69%	+14.19%
SRZN Surrozen	+0.72%	+6.61%	+53.18%	+19.66%	+82.82%
VOR Vor Biopharma	-0.47%	+1.01%	-13.48%	-0.21%	-31.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
NBTX Nanobiotix	$25.83 +7.0%	$33.80	$14.78 ▼ $57.14	$1.23B	0.79	149,622 shs	165,343 shs
SRZN Surrozen	$25.32 +0.7%	$23.69	$11.39 ▼ $37.83	$291.88M	0.47	1.22 million shs	118,837 shs
VOR Vor Biopharma	$18.94 -0.5%	$21.31	$6.50 ▼ $28.66	$1.13B	1.78	1.02 million shs	817,350 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.22%
NBTX Nanobiotix	+7.00%	+21.38%	-25.13%	-34.69%	+14.19%
SRZN Surrozen	+0.72%	+6.61%	+53.18%	+19.66%	+82.82%
VOR Vor Biopharma	-0.47%	+1.01%	-13.48%	-0.21%	-31.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	1.00	Sell	N/A	N/A
NBTX Nanobiotix	2.50	Moderate Buy	$46.67	80.67% Upside
SRZN Surrozen	2.71	Moderate Buy	$48.33	90.89% Upside
VOR Vor Biopharma	2.90	Moderate Buy	$38.00	100.63% Upside

Current Analyst Ratings Breakdown

Latest SRZN, NBTX, VOR, and CVAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	VOR Vor Biopharma	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	NBTX Nanobiotix	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	SRZN Surrozen	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	VOR Vor Biopharma	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/25/2026	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$44.00 ➝ $54.00
9/15/2026	NBTX Nanobiotix	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$64.00
9/14/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D+) ➝ Hold (C-)
8/20/2026	SRZN Surrozen	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$51.00
8/20/2026	SRZN Surrozen	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$51.00
8/12/2026	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$18.00 ➝ $27.00
8/11/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D-) ➝ Sell (D+)

(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
NBTX Nanobiotix	$36.87M	35.61	N/A	N/A	($1.97) per share	-13.11
SRZN Surrozen	$11.51M	25.54	N/A	N/A	($19.21) per share	-1.32
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
NBTX Nanobiotix	-$27.11M	N/A	N/A	161.44	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	-$242.03M	-$40.55	N/A	N/A	N/A	-2,885.33%	N/A	-93.62%	11/6/2026 (Estimated)
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest SRZN, NBTX, VOR, and CVAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	SRZN Surrozen	-$1.1039	N/A	N/A	N/A	$0.48 million	N/A
8/11/2026	Q2 2026	VOR Vor Biopharma	-$0.69	-$0.80	-$0.11	-$1.16	N/A	N/A
8/6/2026	Q2 2026	SRZN Surrozen	-$1.29	-$0.41	+$0.88	-$0.41	$0.47 million	$5.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.03	3.70	3.69
NBTX Nanobiotix	N/A	1.44	N/A
SRZN Surrozen	N/A	12.14	12.14
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
NBTX Nanobiotix	38.81%
SRZN Surrozen	66.57%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
NBTX Nanobiotix	3.45%
SRZN Surrozen	31.74%
VOR Vor Biopharma	0.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
NBTX Nanobiotix	97	50.83 million	49.07 million	Optionable
SRZN Surrozen	44	11.61 million	7.93 million	Optionable
VOR Vor Biopharma	76	59.16 million	59.00 million	Optionable

SRZN, NBTX, VOR, and CVAC Headlines

Recent News About These Companies

William Blair initiates coverage of Vor Biopharma at outperform

October 21 at 10:47 AM | msn.com

William Blair Initiates Vor Biopharma at Outperform

October 21 at 10:47 AM | marketscreener.comM

Vor Biopharma (NASDAQ:VOR) Now Covered by Analysts at William Blair

October 21 at 7:05 AM | marketbeat.com

Wells Fargo Keeps Their Buy Rating on Vor Biopharma (VOR)

October 19 at 10:18 AM | theglobeandmail.com

Vor Biopharma (NASDAQ:VOR) Upgraded to Strong-Buy at Citigroup

October 17, 2026 | marketbeat.com

Vor Biopharma (NASDAQ:VOR) Shares Climb 7.2% - Time to Buy?

October 15, 2026 | marketbeat.com

Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus

October 9, 2026 | uk.finance.yahoo.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 5, 2026 | globenewswire.com

Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)

October 4, 2026 | finance.yahoo.com

Vor Biopharma (NASDAQ:VOR) Stock Jumps 5.3% - Here's What Happened

September 30, 2026 | marketbeat.com

Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | finanznachrichten.de

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | marketscreener.comM

Vor Biopharma en hausse après la publication de résultats encourageants concernant un médicament contre les maladies auto-immunes

September 29, 2026 | boursorama.comB

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | globenewswire.com

Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus

September 29, 2026 | theglobeandmail.com

Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Average Price Target of $41.71 According to Brokerages

September 28, 2026 | marketbeat.com

【VOR】Vor Biopharma

September 23, 2026 | note.comN

Vor Biopharma no fórum Stifel 2026: telitacicept aposta em dupla estratégia

September 23, 2026 | br.investing.com

Vor Biopharma在Stifel 2026论坛上阐述telitacicept双路径布局

September 23, 2026 | cn.investing.com

Vor Biopharma al forum Stifel 2026: telitacicept punta su doppia strategia

September 23, 2026 | it.investing.com

Vor Biopharma en foro Stifel 2026: telitacicept avanza en doble vía

September 23, 2026 | mx.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SRZN, NBTX, VOR, and CVAC Company Descriptions

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 10/20/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Nanobiotix NASDAQ:NBTX

$25.83 +1.69 (+7.00%)

Closing price 10/21/2026 04:00 PM Eastern

Extended Trading

$27.40 +1.57 (+6.08%)

As of 06:45 AM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Surrozen NASDAQ:SRZN

$25.32 +0.18 (+0.72%)

Closing price 10/21/2026 04:00 PM Eastern

Extended Trading

$25.32 0.00 (-0.02%)

As of 05:08 AM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Vor Biopharma NASDAQ:VOR

$18.94 -0.09 (-0.47%)

Closing price 10/21/2026 04:00 PM Eastern

Extended Trading

$18.91 -0.03 (-0.15%)

As of 06:00 AM Eastern

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRZN, NBTX, VOR, and CVAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRZN, NBTX, VOR, and CVAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRZN, NBTX, VOR, and CVAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SRZN, NBTX, VOR, and CVAC Company Descriptions

CureVac NASDAQ:CVAC

Nanobiotix NASDAQ:NBTX

Surrozen NASDAQ:SRZN

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRZN, NBTX, VOR, and CVAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRZN, NBTX, VOR, and CVAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRZN, NBTX, VOR, and CVAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SRZN, NBTX, VOR, and CVAC Company Descriptions

CureVac NASDAQ:CVAC

Nanobiotix NASDAQ:NBTX

Surrozen NASDAQ:SRZN

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools